Veracyte
Open
$47.23
Prev. Close
$47.24
High
$47.34
Low
$47.15
Market Snapshot
$3.76B
42.7
0.32
$445.76M
755
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The company is headquartered in South San Francisco, California and currently employs 755 full-time employees. The company went IPO on 2013-10-30. The firm enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The firm offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). The company has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The company is headquartered in South San Francisco, California and currently employs 755 full-time employees. The company went IPO on 2013-10-30. The firm enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The firm offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). The company has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
Recently from Cashu
Veracyte Launches Prosigna Test to Enhance Personalized Cancer Diagnostics and Treatment Strategies.
Veracyte Inc (Ticker: VCYT) has made significant strides in the oncology diagnostics sector with the recent launch of its Prosigna Breast Risk of Recurrence test. This development coincides with the r…
Veracyte Launches Prosigna Test to Enhance Breast Cancer Recurrence Assessment and Patient Care.
Veracyte positions itself at the forefront of cancer diagnostics with the launch of its Prosigna Breast Risk of Recurrence test. This product introduction is significant as it indicates an expansion o…
Veracyte Reports 20% Revenue Growth and Strategic Expansion in Genomic Diagnostics
Veracyte's Strategic Growth in Genomic Diagnostics Veracyte, a leader in the diagnostics sector, showcases a robust performance in its fourth quarter of 2026, spotlighting the increasing adoption of i…
Veracyte Reports Strong Q4 Earnings Fueled by Surging Demand for Genomic Testing Solutions
Veracyte Reports Strong Q4 Results Amid Growing Demand for Genomic Testing Veracyte (NASDAQ:VCYT) currently experiences robust momentum in the diagnostics market, as reflected in its recently announce…